07 Mar 2025 Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Investors | Therapeutics
07 Mar 2025 Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update Diagnostics | Investors
16 Jan 2025 Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers Investors | Therapeutics
17 Dec 2024 Research & Development Spotlight Series – Episode 7 Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
12 Dec 2024 Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment Investors | Therapeutics
27 Nov 2024 Peel Hunt Healthcare & Life Sciences Podcast with Christina Coughlin Investors | Podcasts and Videos | Therapeutics
08 Nov 2024 Video presentations from R&D Spotlight: ‘Next Generation of pre|CISION® Medicines’ Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics